ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-FR-alpha-antibody-drug-conjugate
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-FR-alpha-antibody-drug-conjugate
9
trial(s) found.
NCT06555744
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors (
ZWI-ZW191-101
)
anti-FR-alpha antibody-drug conjugate
Solid tumour
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06365853
Advanced
Phase 2
Recruiting
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Patients With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (
IMGN853-0424
)
anti-FR-alpha antibody-drug conjugate
Ovarian cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2305 - New Lambton Heights - Newcastle Private Hospital
VIC
3168 - Clayton - Monash Medical Centre
NCT05870748
Advanced
Phase 2 / Phase 3
Recruiting
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (
STRO-002-GM3
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian cancer
Platinum resistant ovarian cancer
Primary peritoneal serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NZ
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Lung adenocarcinoma
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05498597
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours (
AMT-151-01
)
anti-FR-alpha antibody-drug conjugate
Adenocarcinoma
Cancer
Carcinoma
Endometrial cancer
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Lung adenocarcinoma
Ovarian cancer
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Solid tumour
Triple-negative breast cancer
Uterine serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT05445778
Curative
Phase 3
Recruiting
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (
GLORIOSA
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Fallopian tube cancer
Ovarian cancer
Peritoneal cancer
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4215 - Southport - Gold Coast University Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT05613088
Advanced
Phase 2
Active not recruiting
A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (
CA116-001
)
anti-FR-alpha antibody-drug conjugate
Cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05577715
Advanced
Phase 2
Terminated
A Phase 2, Open-label, Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies (
CA116-003
)
anti-FR-alpha antibody-drug conjugate
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Active not recruiting (1)
Terminated (1)
Recruitment Country and State
NSW (8)
VIC (6)
WA (5)
QLD (4)
SA (2)
NZ (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (1)
Phase 2 (3)
Phase 2 / Phase 3 (1)
Phase 3 (1)
Trial Type
Advanced (8)
Curative (1)
Cancer Therapy Class
FR-alpha
100%
VEGF
33%
PARP
11%
PARP1-selective
11%
Facility
3168 - Clayton - Monash Medical Centre (3)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2031 - Randwick - Prince of Wales Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
6009 - Nedlands - One Clinical Research (1)
3121 - Richmond - Epworth Freemasons Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4032 - Chermside - The Prince Charles Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2500 - Wollongong - Wollongong Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
Cancer Type
Cancer
Solid tumour
Gynaecological cancer
Ovarian cancer
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Breast adenocarcinoma
Breast cancer
Endometrial cancer
Gastrointestinal cancer
Pancreatic cancer
Pancreatobiliary cancer
Triple-negative breast cancer
Upper gastrointestinal cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
Ovarian adenocarcinoma
Peritoneal cancer
Lung adenocarcinoma
Non-squamous non-small-cell lung cancer
Cervical cancer
Colorectal cancer
HPV-related cancer
HPV16-positive cancer
Lower gastrointestinal cancer
Viral-related cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
High-grade serous ovarian cancer
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Primary peritoneal serous carcinoma
Adenocarcinoma
Carcinoma
Endometrial adenocarcinoma
Endometrial carcinoma
Endometrial clear cell carcinoma
Endometrial endometrioid carcinoma
Exocrine pancreatic cancer
Mesothelioma
Ovarian clear cell carcinoma
Ovarian endometrioid adenocarcinoma
Pancreatic adenocarcinoma
Pleural mesothelioma
Uterine serous carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy